Please assess the completion status of the following clinical trial:

Trial Title: A Study to Compare the Effects of Exenatide and Sitagliptin on Postprandial Glucose in Subjects With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Treatment with metformin for at least 2 months~* Has HbA1c 7.0% to 11.0%, inclusive, at screening~* Body mass index (BMI)25 kg/m\^2 to 45 kg/m\^2, inclusive~* List of medications that are not allowed or the patient has been on stable treatment for at least 2 months:~  * Hormone replacement therapy (female subjects)~ * Oral contraceptives (female subjects)~ * Antihypertensive agents~ * Lipid-lowering agents~ * Thyroid replacement therapy~Exclusion Criteria~* Has been treated with exenatide (BYETTA®) or any DPP-4 inhibitor prior to screening~* Received any study medication or participated in any type of clinical trial within 30 days prior to screening~* Has donated blood within 60 days of screening visit or is planning to donate blood during the study~* Treated with any of the following medications:~  * Sulfonylurea or Thiazolidinedione within 3 months of screening;~ * Alpha-glucosidase inhibitor, meglitinide, nateglinide, or pramlintide (SYMLIN®)within 30 days of screening;~ * Insulin within 2 weeks prior to screening or insulin for longer than 1 week within 6 months of screening;~ * Drugs that directly affect gastrointestinal motility, including but not limited to, anticholinergics, macrolide antibiotics, dopamine antagonists, opioids, and Reglan®(metoclopramide);~ * Systemic corticosteroids by oral, intravenous, or intramuscular route; or potent, inhaled, or intrapulmonary (including ADVAIR®) steroids known to have a high rate of systemic absorption;

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Sequence A (Type: EXPERIMENTAL): None
- Sequence B (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).